Involvement of endogenous CCK and CCK 1 receptors in colonic motor function

G. Varga, András Bálint, B. Burghardt, Massimo D'Amato

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Cholecystokinin (CCK) is a brain-gut peptide; it functions both as a neuropeptide and as a gut hormone. Although the pancreas and the gallbladder were long thought to be the principal peripheral targets of CCK, CCK receptors are found throughout the gut. It is likely that CCK has a physiological role not only in the stimulation of pancreatic and biliary secretions but also in the regulation of gastrointestinal motility. The motor effects of CCK include postprandial inhibition of gastric emptying and inhibition of colonic transit. It is now evident that at least two different receptors, CCK 1 and CCK 2 (formerly CCK-A and CCK-B, respectively), mediate the actions of CCK. Both localization and functional studies suggest that the motor effects of CCK are mediated by CCK 1 receptors in humans. Since CCK is involved in sensory and motor responses to distension in the intestinal tract, it may contribute to the symptoms of constipation, bloating and abdominal pain that are often characteristic of functional gastrointestinal disorders in general and irritable bowel syndrome (IBS), in particular. CCK 1 receptor antagonists are therefore currently under development for the treatment of constipation-predominant IBS. Clinical studies suggest that CCK 1 receptor antagonists are effective facilitators of gastric emptying and inhibitors of gallbladder contraction and can accelerate colonic transit time in healthy volunteers and patients with IBS. These drugs are therefore potentially of great value in the treatment of motility disorders such as constipation and constipation-predominant IBS.

Original languageEnglish
Pages (from-to)1275-1284
Number of pages10
JournalBritish Journal of Pharmacology
Volume141
Issue number8
DOIs
Publication statusPublished - Apr 2004

Fingerprint

Cholecystokinin Receptors
Cholecystokinin
Irritable Bowel Syndrome
Constipation
Gastric Emptying
Gallbladder
Gastrointestinal Motility
Gastrointestinal Diseases
Neuropeptides
Abdominal Pain
Pancreas
Healthy Volunteers
Hormones

Keywords

  • CCK receptor antagonist
  • Cholecystokinin
  • Colon
  • Irritable bowel syndrome

ASJC Scopus subject areas

  • Pharmacology

Cite this

Involvement of endogenous CCK and CCK 1 receptors in colonic motor function. / Varga, G.; Bálint, András; Burghardt, B.; D'Amato, Massimo.

In: British Journal of Pharmacology, Vol. 141, No. 8, 04.2004, p. 1275-1284.

Research output: Contribution to journalArticle

Varga, G. ; Bálint, András ; Burghardt, B. ; D'Amato, Massimo. / Involvement of endogenous CCK and CCK 1 receptors in colonic motor function. In: British Journal of Pharmacology. 2004 ; Vol. 141, No. 8. pp. 1275-1284.
@article{09229ae0b00d496cb96f64a18aad57d9,
title = "Involvement of endogenous CCK and CCK 1 receptors in colonic motor function",
abstract = "Cholecystokinin (CCK) is a brain-gut peptide; it functions both as a neuropeptide and as a gut hormone. Although the pancreas and the gallbladder were long thought to be the principal peripheral targets of CCK, CCK receptors are found throughout the gut. It is likely that CCK has a physiological role not only in the stimulation of pancreatic and biliary secretions but also in the regulation of gastrointestinal motility. The motor effects of CCK include postprandial inhibition of gastric emptying and inhibition of colonic transit. It is now evident that at least two different receptors, CCK 1 and CCK 2 (formerly CCK-A and CCK-B, respectively), mediate the actions of CCK. Both localization and functional studies suggest that the motor effects of CCK are mediated by CCK 1 receptors in humans. Since CCK is involved in sensory and motor responses to distension in the intestinal tract, it may contribute to the symptoms of constipation, bloating and abdominal pain that are often characteristic of functional gastrointestinal disorders in general and irritable bowel syndrome (IBS), in particular. CCK 1 receptor antagonists are therefore currently under development for the treatment of constipation-predominant IBS. Clinical studies suggest that CCK 1 receptor antagonists are effective facilitators of gastric emptying and inhibitors of gallbladder contraction and can accelerate colonic transit time in healthy volunteers and patients with IBS. These drugs are therefore potentially of great value in the treatment of motility disorders such as constipation and constipation-predominant IBS.",
keywords = "CCK receptor antagonist, Cholecystokinin, Colon, Irritable bowel syndrome",
author = "G. Varga and Andr{\'a}s B{\'a}lint and B. Burghardt and Massimo D'Amato",
year = "2004",
month = "4",
doi = "10.1038/sj.bjp.0705769",
language = "English",
volume = "141",
pages = "1275--1284",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Involvement of endogenous CCK and CCK 1 receptors in colonic motor function

AU - Varga, G.

AU - Bálint, András

AU - Burghardt, B.

AU - D'Amato, Massimo

PY - 2004/4

Y1 - 2004/4

N2 - Cholecystokinin (CCK) is a brain-gut peptide; it functions both as a neuropeptide and as a gut hormone. Although the pancreas and the gallbladder were long thought to be the principal peripheral targets of CCK, CCK receptors are found throughout the gut. It is likely that CCK has a physiological role not only in the stimulation of pancreatic and biliary secretions but also in the regulation of gastrointestinal motility. The motor effects of CCK include postprandial inhibition of gastric emptying and inhibition of colonic transit. It is now evident that at least two different receptors, CCK 1 and CCK 2 (formerly CCK-A and CCK-B, respectively), mediate the actions of CCK. Both localization and functional studies suggest that the motor effects of CCK are mediated by CCK 1 receptors in humans. Since CCK is involved in sensory and motor responses to distension in the intestinal tract, it may contribute to the symptoms of constipation, bloating and abdominal pain that are often characteristic of functional gastrointestinal disorders in general and irritable bowel syndrome (IBS), in particular. CCK 1 receptor antagonists are therefore currently under development for the treatment of constipation-predominant IBS. Clinical studies suggest that CCK 1 receptor antagonists are effective facilitators of gastric emptying and inhibitors of gallbladder contraction and can accelerate colonic transit time in healthy volunteers and patients with IBS. These drugs are therefore potentially of great value in the treatment of motility disorders such as constipation and constipation-predominant IBS.

AB - Cholecystokinin (CCK) is a brain-gut peptide; it functions both as a neuropeptide and as a gut hormone. Although the pancreas and the gallbladder were long thought to be the principal peripheral targets of CCK, CCK receptors are found throughout the gut. It is likely that CCK has a physiological role not only in the stimulation of pancreatic and biliary secretions but also in the regulation of gastrointestinal motility. The motor effects of CCK include postprandial inhibition of gastric emptying and inhibition of colonic transit. It is now evident that at least two different receptors, CCK 1 and CCK 2 (formerly CCK-A and CCK-B, respectively), mediate the actions of CCK. Both localization and functional studies suggest that the motor effects of CCK are mediated by CCK 1 receptors in humans. Since CCK is involved in sensory and motor responses to distension in the intestinal tract, it may contribute to the symptoms of constipation, bloating and abdominal pain that are often characteristic of functional gastrointestinal disorders in general and irritable bowel syndrome (IBS), in particular. CCK 1 receptor antagonists are therefore currently under development for the treatment of constipation-predominant IBS. Clinical studies suggest that CCK 1 receptor antagonists are effective facilitators of gastric emptying and inhibitors of gallbladder contraction and can accelerate colonic transit time in healthy volunteers and patients with IBS. These drugs are therefore potentially of great value in the treatment of motility disorders such as constipation and constipation-predominant IBS.

KW - CCK receptor antagonist

KW - Cholecystokinin

KW - Colon

KW - Irritable bowel syndrome

UR - http://www.scopus.com/inward/record.url?scp=2442457964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442457964&partnerID=8YFLogxK

U2 - 10.1038/sj.bjp.0705769

DO - 10.1038/sj.bjp.0705769

M3 - Article

VL - 141

SP - 1275

EP - 1284

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 8

ER -